BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36151778)

  • 1. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
    Yang G; Williams R; Wang L; Farhadfar N; Chen Y; Loiacono AT; Bian J; Holliday LS; Katz J; Gong Y
    J Bone Miner Res; 2022 Dec; 37(12):2466-2471. PubMed ID: 36151778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
    Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
    J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
    Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
    Liu FC; Luk KC; Chen YC
    Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress on medication-related osteonecrosis of the jaw].
    Wang QZ; Liu JY; Pan J
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2018 Oct; 36(5):568-572. PubMed ID: 30465354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
    Yuan A; Munz A; Reinert S; Hoefert S
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
    Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.